Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care.
El-Galaly TC, Gaidzik VI, Gaman MA, Antic D, Okosun J, Copland M, Sexl V, Fielding AK, Doeswijk R, Parker H, Dreyling M, Döhner K, Almeida AM, Macintyre E, Gribben JG, Grønbæk K. El-Galaly TC, et al. Among authors: dohner k. Hemasphere. 2023 Feb 21;7(3):e842. doi: 10.1097/HS9.0000000000000842. eCollection 2023 Mar. Hemasphere. 2023. PMID: 36844176 Free PMC article. No abstract available.
Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities.
Lubbers BR, Dombrink I, Kalina T, Hofmans M, Bruun MS, Stanworth SJ, Béné MC, Döhner K, Brüggemann M, Macintyre E, van Dongen JJM. Lubbers BR, et al. Among authors: dohner k. Hemasphere. 2023 Mar 7;7(4):e865. doi: 10.1097/HS9.0000000000000865. eCollection 2023 Apr. Hemasphere. 2023. PMID: 36911048 Free PMC article. No abstract available.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Among authors: dohner k. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.
Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET.
Wille K, Brouka M, Bernhardt J, Rüfer A, Niculescu-Mizil E, Gotic M, Isfort S, Koschmieder S, Barbui T, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Stegelmann F, Döhner K, Kiladjian JJ, Griesshammer M. Wille K, et al. Among authors: dohner k. Hemasphere. 2023 May 2;7(5):e882. doi: 10.1097/HS9.0000000000000882. eCollection 2023 May. Hemasphere. 2023. PMID: 37153877 Free PMC article. No abstract available.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Among authors: dohner k. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. Ann Hematol. 2024. PMID: 38438627 Free PMC article.
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.
Thomas J, Rehman UU, Bresser H, Grishina O, Pfeifer D, Sollier E, Döhner K, Plass C, Becker H, Schmoor C, de Wit M, Lübbert M. Thomas J, et al. Among authors: dohner k. Clin Epigenetics. 2024 Sep 11;16(1):126. doi: 10.1186/s13148-024-01737-4. Clin Epigenetics. 2024. PMID: 39261919 Free PMC article.
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, Heuser M, Hou HA, Pratcorona M, Hills RK, Metzeler KH, Fenwarth L, Dolnik A, Terre C, Kopp K, Blau O, Szyska M, Christen F, Krönke J, Vasseur L, Löwenberg B, Esteve J, Valk PJM, Duchmann M, Chou WC, Linch DC, Döhner H, Gale RE, Döhner K, Bullinger L, Yoshida K, Damm F. Halik A, et al. Among authors: dohner k. J Hematol Oncol. 2024 Aug 19;17(1):70. doi: 10.1186/s13045-024-01590-1. J Hematol Oncol. 2024. PMID: 39160538 Free PMC article.
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison CN, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kröger N, Kuykendall AT, Loscocco GG, Mascarenhas JO, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani AD, Patel AA, Pemmaraju N, Rambaldi A, Rampal RK, Sirhan S, Szuber N, Talpaz M, Vachhani P, Vannucchi AM, Barbui T. Tefferi A, et al. Among authors: dohner k. Blood. 2024 Aug 8:blood.2024025802. doi: 10.1182/blood.2024025802. Online ahead of print. Blood. 2024. PMID: 39116296
351 results